close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

162.55 +0.62 (+0.38%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
Genmab (GMAB) Q3 2026 Earnings Call Transcript ↗
Strong royalties and pipeline progress, but litigation risks remain in focus. 
Via The Motley Fool
Topics Earnings
News headline image
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript ↗
Royalty declines and a litigation gain shaped the quarter's results. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Novartis: 3 Key Takeaways for Long-Term Investors ↗
Operating margins are on track to hit 40% by 2029 as cost discipline accelerates alongside new drug launches. 
Via The Motley Fool
Topics Earnings Intellectual Property
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile ↗
Via Chartmill
Advances in Cancer Care Are Moving Closer to Home
(BPT) - Key takeaways: 
Via Brandpoint
News headline image
Should You Buy Royalty Pharma Stock Before Nov. 4? ↗
Don't expect earnings day to sustain the stock's recent rally. 
Via The Motley Fool
News headline image
What Novartis (NVS) Said on Its Q3 Earnings Call ↗
Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Novartis (NVS) Q3 2026 Earnings Call Transcript ↗
Priority brands offset generic erosion as margin expands and pipeline advances. 
Via The Motley Fool
Topics Earnings
News headline image
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report ↗
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker fell short. 
Via Investor's Business Daily
News headline image
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity ↗
Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion... 
Via MarketBeat
Topics ETFs
News headline image
If Economists Are Correct About the Future of AI, Here Are 2 Global ETFs to Buy -- and 2 to Avoid ↗
A recent survey shows reasons to be bullish on international stocks. But some global ETFs look more bullish than others. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
Where You Live Shouldn't Limit Your Cancer Care
(BPT) - Key takeaways: 
Via Brandpoint
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains. 
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
From Pomerantz LLP
Via GlobeNewswire
News headline image
At the Longevity Investors Conference in Gstaad, Investors Test Which Longevity Claims Hold Up
DATELINE]As longevity research moves from animal models into human trials, investors are asking a sharper question: what is science, and... 
Via Newsfile
News headline image
Leaders Face Stark Warning from Silicon Valley Veteran – The Old Way of Working is Dead
Via Get News
Topics Artificial Intelligence
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride. 
Via The Motley Fool
News headline image
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 ↗
The pharmaceutical giant's track record in past bear markets is fairly impressive. 
Via The Motley Fool
Topics Economy Intellectual Property Stocks
News headline image
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares ↗
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. 
Via Investor's Business Daily
News headline image
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much. 
Via The Motley Fool
News headline image
Amgen Drops 10% on a Trial It Didn't Even Run ↗
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact. 
Via MarketBeat
News headline image
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks ↗
Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks. 
Via Benzinga
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
News headline image
2025 R&D Spending And Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.